Year None2024202320222021202020192018201720162015 Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update November 12, 2024 at 4:01 PM EST Kezar Life Sciences Announces 1-for-10 Reverse Stock Split October 28, 2024 at 8:30 AM EDT Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan October 17, 2024 at 8:35 AM EDT Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update October 17, 2024 at 8:30 AM EDT Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal October 10, 2024 at 8:30 AM EDT Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis October 4, 2024 at 5:00 PM EDT Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients September 30, 2024 at 8:30 AM EDT Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 4, 2024 at 4:01 PM EDT Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update August 13, 2024 at 4:02 PM EDT Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) July 10, 2024 at 4:01 PM EDT Pagination Current page 1 Page 2 Next page next › Last page last »
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update November 12, 2024 at 4:01 PM EST
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan October 17, 2024 at 8:35 AM EDT
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update October 17, 2024 at 8:30 AM EDT
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal October 10, 2024 at 8:30 AM EDT
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis October 4, 2024 at 5:00 PM EDT
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients September 30, 2024 at 8:30 AM EDT
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 4, 2024 at 4:01 PM EDT
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update August 13, 2024 at 4:02 PM EDT